Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-08-26

Clinical Trial Results: Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating therapies for metastatic castration-resistant prostate cancer has terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Snippet

Sponsor: Amgen | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-08-26